Modified gegen qinlian decoction ameliorates Veillonella parvula-exacerbated ulcerative colitis via restoration of intestinal mucosal barrier function
Open Access
- 21 April 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1803816
Abstract
Introduction: Ulcerative colitis (UC) is being increasingly connected to the pathogen Veillonella parvula (V. parvula). Modified Gegen Qinlian Decoction (MGQD), a traditional Chinese medicine therapy, is used to treat UC. However, the underlying mechanism by which V. parvula exacerbates UC and whether MGQD can alleviate it is unknown. Methods: MGQD therapy was tested on pathogen-free and pseudo-germ-free mice infected with V. parvula. Colitis severity was determined by disease activity index, colon length, and histology. Transmission electron microscopy, Western blot, immunofluorescence, and immunohistochemistry were used to assess the integrity of the intestinal mucosal barrier. In vitro , mouse colonic organoids were utilized to examine the effects of baicalin and puerarin on inflammation-induced downregulation of Muc2 and ZO-1. Results: MGQD therapy dramatically reduced the severity of colitis in both mouse models. MGQD restored the integrity of the mucus and mechanical barriers. Furthermore, baicalin and puerarin reduced inflammation-induced downregulation of Muc2 and ZO-1 in mouse colonic organoids. Discussion: These findings demonstrate that MGQD alleviates intestinal barrier dysfunction caused by V. parvula, providing novel mechanistic insight for the management of chronic colitis.Keywords
Funding Information
- National Institutes of Natural Sciences (82341233)
This publication has 27 references indexed in Scilit:
- Ursolic acid attenuates sarcopenia through IL-17a-related gut-muscle axis in senile diabetic mice and myotube modelThe Journal of Nutritional Biochemistry, 2025
- Morin alleviates DSS-induced ulcerative colitis in mice via inhibition of inflammation and modulation of intestinal microbiotaInternational Immunopharmacology, 2024
- Study on the mechanism of modified Gegen Qinlian decoction in regulating the intestinal flora-bile acid-TGR5 axis for the treatment of type 2 diabetes mellitus based on macro genome sequencing and targeted metabonomics integrationPhytomedicine, 2024
- Narirutin mitigates dextrose sodium sulfate-induced colitis in mice by modulating intestinal floraPhytomedicine, 2024
- Gingerenone A Attenuates Ulcerative Colitis via Targeting IL‐17RA to Inhibit Inflammation and Restore Intestinal Barrier FunctionAdvanced Science, 2024
- Modified Gegen Qinlian decoction ameliorated ulcerative colitis by attenuating inflammation and oxidative stress and enhancing intestinal barrier function in vivo and in vitroJournal of Ethnopharmacology, 2023
- Modified Gegen Qinlian decoction ameliorates DSS-induced chronic colitis in mice by restoring the intestinal mucus barrier and inhibiting the activation of γδT17 cellsPhytomedicine, 2023
- Potential activity of Traditional Chinese Medicine against Ulcerative colitis: A reviewJournal of Ethnopharmacology, 2022
- Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trialJournal of Hepatology, 2022
- Zuojin Pill ameliorates inflammation in indomethacin-induced gastric injury via inhibition of MAPK pathwayJournal of Ethnopharmacology, 2021